Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adavosertib - AstraZeneca

Drug Profile

Adavosertib - AstraZeneca

Alternative Names: AZD-1775; L001739996-008U; MK-1775; MK-1775 hemihydrate

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co
  • Developer AstraZeneca; Canadian Cancer Trials Group; Cancer Research UK; Dana-Farber Cancer Institute; Merck & Co; National Cancer Institute (USA); Samsung Medical Center; University of Birmingham; University of Texas M. D. Anderson Cancer Center; University of Washington
  • Class Aniline compounds; Antineoplastics; Piperazines; Pyrazoles; Pyridines; Pyrimidinones; Small molecules
  • Mechanism of Action WEE1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Endometrial cancer; Fallopian tube cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours; Uterine cancer
  • Phase I Head and neck cancer
  • Preclinical Diffuse large B cell lymphoma
  • No development reported Colorectal cancer; Glioblastoma; Haematological disorders; Vulvovaginal cancer
  • Discontinued Cervical cancer

Most Recent Events

  • 01 Oct 2021 Biomarkers information updated
  • 13 Sep 2021 AstraZeneca initiates enrolment in a phase I trial for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) in September 2021 (NCT04949425)
  • 23 Aug 2021 AstraZeneca plans a phase I pharmacokinetic trial for Solid tumours (Late stage disease, Metastatic disease, Second-line or greater therapy, In Adults, In the elderly) in United Kingdom (PO) in September 2021 (NCT05008913)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top